CRISPR Therapeutics Archives

Latest Posts

News and Trends 26 Oct 2015

Wow, Europe’s leading CRISPR Biotech signs monster €2.29 Billion Deal

CRIPSR’s hype is not going down yet. CRIPSR/Cas9 or Cpf1 is a revolutionising gene editing tool, which almost won the Nobel Prize of this year (it won nearly all the other biology prizes already). It also caught great interest from the industry and venture capitalists. The leading Biotechs includes: Editas, Boston-based and clozed a $120M found […]

October 26, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 30 Sep 2015

CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?

CRISPR is already revolutionizing Biotechnology. However, like every biotech revolution, there then follows a patent war. But the discovery of a new gene editing protein (Cpf1), with the potential of replacing Cas9, could change this status-quo. As Business Insider puts its, CRISPR is “the biggest biotech discovery of the century“. And its true, it really changed […]

September 30, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

CRISPR Therapeutics reinforces its Team with Top Executives from Pfizer and McKinsey

A new strategic movement in the hot CRISPR field: CRISPR Therapeutics ramps up its leadership team with Samarth Kulkarni as its new Chief Business Officer and Michael Bruce as Senior Vice President to moderate program portfolio and alliance management. In the meantime, CRISPR’s main competitor EditasMedicine procured €108M to accelerate its CRISPR-based therapies in clinical state. […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 30 Apr 2015

Gene-editing Technology war continues while CRISPR Therapeutics raised €79.5M

As the CRISPR-Cas9 war still goes on, CRISPR Therapeutics closed a Series A and B financing round with €79.5M. The oversubscribed financing rounds were led by strategic investors, GlaxoSmithKline‘s SR One and Celgene Corporation, respectively and also included other actors already known by the company, such as Versant Ventures, along with new ones namely New […]

April 30, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Apr 2015

CRISPR Therapeutics opens Boston R&D Office to Win the CRISPR War

CRISPR Therapeutics appointed Bill Lundberg to Chief Scientific Officer to lead the company’s development programs and to spearhead the creation of its R&D operations in Cambridge, Massachusetts. The biopharmaceutical company was founded in Basel, Switzerland, by Emanuelle Charpentier, one of the pioneer scientists in the CRISPR field. The company is focused on translating CRISPR-Cas9 gene-editing […]

April 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 21 Jan 2015

Review: The CRISPR’s Therapeutical revolution

Six years ago, a new sophisticated prokaryotic defense system, was identified in the structure complex CRISPR-Cas9 (CRISPR, clustered regularly interspaced short palindromic repeats; Cas, CRISPR associated nuclease). “Resistance is acquired by incorporating short stretches of invading DNA sequences in genomic CRISPR loci ” Brouns, S. J. J., et al. (2008). The CRISPR repeat sequence has […]

January 21, 2015 - 4 minutesmins - By Cédric Brock

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us